Activation of Signalling by the Activin Receptor Complex
Overview
Authors
Affiliations
Activin exerts its effects by simultaneously binding to two types of p rotein serine/threonine kinase receptors, each type existing in various isoforms. Using the ActR-IB and ActR-IIB receptor isoforms, we have investigated the mechanism of activin receptor activation. ActR-IIB are phosphoproteins with demonstrable affinity for each other. However, activin addition strongly promotes an interaction between these two proteins. Activin binds directly to ActR-IIB, and this complex associates with ActR-IB, which does not bind ligand on its own. In the resulting complex, ActR-IB becomes hyperphosphorylated, and this requires the kinase activity of ActR-IIB. Mutation of conserved serines and threonines in the GS domain, a region just upstream of the kinase domain in ActR-IB, abrogates both phosphorylation and signal propagation, suggesting that this domain contains phosphorylation sites required for signalling. ActR-IB activation can be mimicked by mutation of Thr-206 to aspartic acid, which yields a construct, ActR-IB(T206D), that signals in the absence of ligand. Furthermore, the signalling activity of this mutant construct is undisturbed by overexpression of a dominant negative kinase-defective ActR-IIB construct, indicating that ActR-IB(T206D) can signal independently of ActR-IIB. The evidence suggests that ActR-IIB acts as a primary activin receptor and ActR-IB acts as a downstream transducer of activin signals.
Kumaraguru S, Morgan J, Wong F Sci Adv. 2025; 11(8):eadq5842.
PMID: 39970202 PMC: 11838000. DOI: 10.1126/sciadv.adq5842.
Bromer F, Lodberg A, Eijken M, Andersen C, Poulsen M, Thomsen J J Cachexia Sarcopenia Muscle. 2025; 16(1):e13718.
PMID: 39887865 PMC: 11780395. DOI: 10.1002/jcsm.13718.
Wiens K, Wasti N, Ulloa O, Klegeris A Molecules. 2024; 29(23).
PMID: 39683685 PMC: 11643984. DOI: 10.3390/molecules29235525.
Potential Roles of Activin in Head and Neck Squamous Cell Carcinoma Progression and Mortality.
Buryska S, Patel K, Wuertz B, Gaffney P, Ondrey F Anticancer Res. 2023; 43(12):5299-5310.
PMID: 38030164 PMC: 11285815. DOI: 10.21873/anticanres.16733.
Allen R, Jones W, Hale M, Warder B, Shore E, Mullins M J Bone Miner Res. 2023; 38(9):1364-1385.
PMID: 37329499 PMC: 11472394. DOI: 10.1002/jbmr.4869.